Walsh T J, Pizzo A
Infectious Diseases Section, National Cancer Institute, Bethesda, Maryland 20892.
Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):460-75. doi: 10.1007/BF01962595.
Systemic mycoses continue to emerge as life-threatening infections. Considerable progress in treating these infections is being achieved through better application of established available antifungal agents (amphotericin B, flucytosine, miconazole and ketoconazole), and through development of promising investigational agents (fluconazole, itraconazole). Systemic fungal infections, however, continue to present major problems, including clinical resistance, microbiological resistance, emergence of new pathogens, and involvement of more immunocompromised patients. The purpose of this paper, therefore, is to review the recent progress and current problems in treatment of systemic fungal infections.
全身性真菌病仍然是威胁生命的感染性疾病。通过更合理地应用现有的抗真菌药物（两性霉素B、氟胞嘧啶、咪康唑和酮康唑）以及开发有前景的研究性药物（氟康唑、伊曲康唑），在治疗这些感染方面已经取得了相当大的进展。然而，全身性真菌感染仍然存在主要问题，包括临床耐药性、微生物耐药性、新病原体的出现以及更多免疫功能低下患者的感染。因此，本文的目的是综述全身性真菌感染治疗的最新进展和当前存在的问题。
